MX2020001856A - Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo. - Google Patents
Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo.Info
- Publication number
- MX2020001856A MX2020001856A MX2020001856A MX2020001856A MX2020001856A MX 2020001856 A MX2020001856 A MX 2020001856A MX 2020001856 A MX2020001856 A MX 2020001856A MX 2020001856 A MX2020001856 A MX 2020001856A MX 2020001856 A MX2020001856 A MX 2020001856A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- intravenous administration
- recombinant mva
- combination therapy
- treating cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000001990 intravenous administration Methods 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La descripción hace referencia a una combinación farmacéutica que consiste en un MVA-TAA (virus vaccinia Ankara modificado con un antígeno asociado con tumor) con un segundo anticuerpo, métodos para reducir el volumen tumoral y/o aumentar la supervivencia de un paciente con cáncer. La combinación comprende además una administración intravenosa de un MVA recombinante que codifica un antígeno asociado con tumor y una administración de un anticuerpo a un paciente con cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17187824 | 2017-08-24 | ||
PCT/EP2018/072789 WO2019038388A1 (en) | 2017-08-24 | 2018-08-23 | POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020001856A true MX2020001856A (es) | 2020-07-13 |
Family
ID=59702586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001856A MX2020001856A (es) | 2017-08-24 | 2018-08-23 | Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11273211B2 (es) |
EP (1) | EP3691675A1 (es) |
JP (1) | JP7202362B2 (es) |
KR (1) | KR20200044000A (es) |
CN (1) | CN111050790A (es) |
AU (1) | AU2018320417A1 (es) |
BR (1) | BR112020003669A2 (es) |
CA (1) | CA3073310A1 (es) |
IL (1) | IL272546B2 (es) |
MX (1) | MX2020001856A (es) |
SG (1) | SG11202001115TA (es) |
WO (1) | WO2019038388A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
WO2022192268A1 (en) * | 2021-03-10 | 2022-09-15 | University Of Iowa Research Foundation | Methods of enhancing antibody therapies |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
EP2112225A1 (en) | 1996-07-25 | 2009-10-28 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Recombinant pox virus for immunization against tumor-associated antigens |
EP1865065A1 (en) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
EP1598425A1 (en) | 2000-11-23 | 2005-11-23 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant |
JP4364643B2 (ja) | 2001-11-30 | 2009-11-18 | アメリカ合衆国 | 前立腺特異抗原のペプチドアゴニストおよびその使用 |
EP1456230A2 (en) | 2001-12-04 | 2004-09-15 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
WO2005012527A1 (en) * | 2003-07-21 | 2005-02-10 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
CA2741724C (en) | 2008-11-27 | 2016-10-04 | Bavarian Nordic A/S | Promoters for recombinant viral expression |
US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
CA2759013C (en) * | 2009-04-17 | 2021-10-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy compositions against cancer and methods |
EP2864487B1 (en) | 2012-06-22 | 2018-12-05 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
WO2014037124A1 (en) * | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
WO2014043535A1 (en) * | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
EP2895191B1 (en) * | 2012-09-14 | 2019-06-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Brachyury protein, adenoviral vectors encoding brachyury protein, and their use |
JP2016502507A (ja) | 2012-10-19 | 2016-01-28 | バヴァリアン・ノルディック・インコーポレイテッド | 癌治療のための組成物および方法 |
SI2912183T1 (sl) | 2012-10-28 | 2020-07-31 | Bavarian Nordic A/S | Promotor Pr13.5 za odzive robustne T-celice in protiteles |
US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
US20160271239A1 (en) | 2013-11-05 | 2016-09-22 | Bavarian Nordic A/S | Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor |
PT3074517T (pt) * | 2013-11-28 | 2021-11-03 | Bavarian Nordic As | Composições e métodos para indução de uma resposta imunitária intensificada usando vetores de poxvírus |
EP3142690B1 (en) * | 2014-05-13 | 2022-02-23 | Bavarian Nordic A/S | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
EP3197490B1 (en) * | 2014-09-26 | 2023-06-21 | Bavarian Nordic A/S | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin |
JP6851364B2 (ja) | 2015-07-31 | 2021-03-31 | バヴァリアン・ノルディック・アクティーゼルスカブ | ポックスウイルスにおける発現を増強するためのプロモーター |
US20220000997A1 (en) * | 2019-02-19 | 2022-01-06 | Bavarian Nordic A/S | Therapy for Treating Cancer with an Intratumoral or Intravenous Administration of a Recombinant MVA Encoding 4-1BBL (CD137L) and/or CD40L |
IL293012A (en) * | 2019-11-20 | 2022-07-01 | Bavarian Nordic As | Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva |
WO2023118508A1 (en) * | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
-
2018
- 2018-08-23 KR KR1020207005076A patent/KR20200044000A/ko not_active Application Discontinuation
- 2018-08-23 CN CN201880054776.8A patent/CN111050790A/zh active Pending
- 2018-08-23 CA CA3073310A patent/CA3073310A1/en active Pending
- 2018-08-23 AU AU2018320417A patent/AU2018320417A1/en active Pending
- 2018-08-23 BR BR112020003669-2A patent/BR112020003669A2/pt unknown
- 2018-08-23 WO PCT/EP2018/072789 patent/WO2019038388A1/en unknown
- 2018-08-23 JP JP2020511314A patent/JP7202362B2/ja active Active
- 2018-08-23 US US16/641,236 patent/US11273211B2/en active Active
- 2018-08-23 EP EP18756447.1A patent/EP3691675A1/en active Pending
- 2018-08-23 MX MX2020001856A patent/MX2020001856A/es unknown
- 2018-08-23 IL IL272546A patent/IL272546B2/en unknown
- 2018-08-23 SG SG11202001115TA patent/SG11202001115TA/en unknown
-
2022
- 2022-03-14 US US17/693,716 patent/US11723964B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2020531524A (ja) | 2020-11-05 |
SG11202001115TA (en) | 2020-03-30 |
AU2018320417A1 (en) | 2020-02-27 |
WO2019038388A1 (en) | 2019-02-28 |
IL272546A (en) | 2020-03-31 |
IL272546B2 (en) | 2024-01-01 |
CN111050790A (zh) | 2020-04-21 |
RU2020111588A3 (es) | 2022-03-29 |
IL272546B1 (en) | 2023-09-01 |
CA3073310A1 (en) | 2019-02-28 |
RU2020111588A (ru) | 2021-09-24 |
US20220249636A1 (en) | 2022-08-11 |
US20200306352A1 (en) | 2020-10-01 |
EP3691675A1 (en) | 2020-08-12 |
JP7202362B2 (ja) | 2023-01-11 |
US11273211B2 (en) | 2022-03-15 |
US11723964B2 (en) | 2023-08-15 |
BR112020003669A2 (pt) | 2020-09-01 |
KR20200044000A (ko) | 2020-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
MX2019010972A (es) | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. | |
MX2020008977A (es) | Formulaciones de anticuerpos de her2 subcutaneas. | |
MX2019012462A (es) | Terapia combinada. | |
MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
RU2016122035A (ru) | Комбинированное лекарственное средство для лечения рака с использованием поксвируса, экспрессирующего опухолевый антиген, и антагониста и/или агониста ингибитора имунной контрольной точки | |
EA201790799A1 (ru) | Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей | |
MX2019011148A (es) | Metodos de tratamiento. | |
MX2022008868A (es) | Tratamiento del cancer con tg02. | |
WO2012071561A3 (en) | Anti-il-6 antibodies for the treatment of anemia | |
MX2019012464A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. | |
EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
WO2018083220A3 (en) | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines | |
MX2021005560A (es) | Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l). | |
WO2016051398A8 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
MX2019003546A (es) | Virus oncoliticos optimizados y usos de los mismos. | |
MX2018015172A (es) | Metodos para tratar cancer pancreatico. | |
MX2023008849A (es) | Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico. | |
MX2022005345A (es) | Terapia de combinación para el tratamiento de cáncer cerebral. | |
MX2020001856A (es) | Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo. | |
MX2017010341A (es) | Terapia para cancer con un parvovirus combinado con bevacizumab. | |
SG11202103097QA (en) | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy | |
EA201990370A1 (ru) | Терапия рака, связанная с crebbp | |
WO2019168897A3 (en) | Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents | |
MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. |